Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Conchon, Monika, Freitas, Carla Maria Boquimpani de Moura, Rego, Maria Aparecida do Carmo, Braga Junior, José Wilson Ramos
Formato: Artigo
Idioma:Inglês
Publicado em: Associação Brasileira de Hematologia e Hemoterapia 2011
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3520638/
https://ncbi.nlm.nih.gov/pubmed/23284261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5581/1516-8484.20110034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados